Mercy BioAnalytics raised $59 million in Series B funding led by Novalis and Sozo Ventures to advance commercialization of its extracellular vesicle-based blood tests for early ovarian and lung cancer detection. Their platform detects tumor-specific proteins on EVs and has received FDA breakthrough device designation for ovarian cancer screening. The financing aims to accelerate clinical, regulatory, and commercial milestones, with new board appointee Rob Freelen joining to support growth.